Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 5/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353173 | 0.99 | IGF1R (0.53) | IGF1RHTTMEN1KMT2AHSD17B10 | |
| SCHEMBL30353131 | 0.99 | IGF1R (0.53) | IGF1RHTTMEN1KMT2AHSD17B10 | |
| SCHEMBL30353150 | 0.90 | PAK4 (0.53) | IGF1RHTTMEN1KMT2AHSD17B10 | |
| SCHEMBL30353192 | 0.89 | NTRK1 (0.50) | IGF1RPAK4AURKAAURKBJAK2 | |
| SCHEMBL30353180 | 0.86 | IGF1R (0.51) | IGF1RHTTMEN1KMT2AHSD17B10 | |
| SCHEMBL30353133 | 0.85 | IGF1R (0.47) | IGF1RHTTMEN1KMT2AHSD17B10 | |
| SCHEMBL30353147 | 0.84 | IGF1R (0.49) | IGF1RHTTMEN1KMT2AHSD17B10 | |
| SCHEMBL30353182 | 0.84 | IGF1R (0.49) | IGF1RHTTMEN1KMT2AHSD17B10 | |
| SCHEMBL30353145 | 0.82 | IGF1R (0.47) | IGF1RHTTMEN1KMT2AHSD17B10 | |
| SCHEMBL30353143 | 0.77 | MEN1 (0.51) | IGF1RHTTMEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | IGF1R 1819/4885HTT 3372/4885MEN1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.